정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 905 | Recruiting | Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19 | Covid19 | Drug: to be given as a treatment | Phase 3 | Salmaniya Medical Complex | OTHER_GOV | 500 | All | 18 Years | Abdulla Kanoo Center,, A'ali, Building 556, Bahrain |
| 904 | Recruiting | Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 | COVID-19 Pneumonia | Drug: CKD-314+SOC Drug: CKD-314 Placebo+SOC |
Phase 3 | Chong Kun Dang Pharmaceutical | INDUSTRY | 586 | All | 18 Years | Korea University Guro Hospital, Seoul, Korea, Republic of |
| 903 | Recruiting | Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 | Covid19 | Biological: Novaferon Biological: Placebo |
Phase 3 | Genova Inc. | INDUSTRY | 914 | All | 18 Years | Casa De Saude, Campinas, Brazil Hospital Base Osorno, Osorno, Chile Hospital Sotero del Rio, Santiago, Chile Fundacion Cardiovascular de Colombia - Instituto del Carazon Floridablanco, Floridablanca, Santander, Colombia |
| 902 | Active, not recruiting | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | Coronavirus Disease 2019 (COVID-19) Pneumonia | Biological: Lenzilumab Drug: Standard of Care |
Phase 3 | Humanigen, Inc. | INDUSTRY | 520 | All | 18 Years | Mayo Clinic, Phoenix, Arizona, United States University of California, Irvine, Irvine, California, United States University of Southern California (USC) Medical Center, Los Angeles, California, United States USC - Los Angeles County Medical Center, Los Angeles, California, United States MedStar Washington Hospital Center, Washington, District of Columbia, United States Mayo Clinic, Jacksonville, Florida, United States AdventHealth Orlando, Orlando, Florida, United States Emory University, Atlanta, Georgia, United States St. Elizabeth Healthcare, Edgewood, Kentucky, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States Mayo Clinic, Rochester, Minnesota, United States Dartmouth-Hitchcock, Lebanon, New Hampshire, United States Saint Barnabas Medical Center, Livingston, New Jersey, United States Mercy Medical Center, Rockville Centre, New York, United States Atrium Health, Charlotte, North Carolina, United States St. David's Healthcare, Austin, Texas, United States St. David's North Austin Medical Center, Austin, Texas, United States Texas Health, Dallas, Texas, United States Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil CPCLIN - Centro de Pesquisas Clinicas de Natal, Natal, Rio Grande Do Norte, Brazil Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil Sociedade Literaria e Caritativa Santo Agostinho, Criciuma, Santa Catarina, Brazil Hospital Dia do Pulmao, Blumenau, Sao Paulo, Brazil Hospital Guilherme Alvaro, Santos, Sao Paulo, Brazil Clinica de Alergia Martti Antila S/S LTDA, Sorocaba, Sao Paulo, Brazil CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA-EPP, Sao Bernardo do Campo, Sao Paulo, Brazil Escola Paulista de Medicina (UNIFESP), Sao Paulo, Brazil Hospital Heliopolis, Sao Paulo, Brazil Hospital Sao Luiz do Jabaquara/IDOR, Sao Paulo, Brazil |
| 901 | Not yet recruiting | Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine | COVID-19 | Biological: CoVLP formulation | Phase 3 | Medicago | INDUSTRY | 900 | All | 18 Years ~ 49 Years | Dawson Clinical Research, Guelph, Ontario, Canada LMC Manna Research, Toronto, Ontario, Canada |
| 900 | Active, not recruiting | Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine | Coronavirus | Biological: Recombinant new coronavirus vaccine (CHO cell) low-dose group Biological: Recombinant new coronavirus vaccine (CHO cells) high-dose group Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group |
Phase 1 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao Yang Hospital | INDUSTRY | 50 | All | 18 Years ~ 59 Years | The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China |
| 899 | Completed | Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults | COVID-19 | Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Phase 1 | CanSino Biologics Inc., Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Jiangsu Province Centers for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Tongji Hospital | INDUSTRY | 108 | All | 18 Years ~ 60 Years | Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China |